PE20210185A1 - Apirasas solubilizadas, metodos y usos - Google Patents
Apirasas solubilizadas, metodos y usosInfo
- Publication number
- PE20210185A1 PE20210185A1 PE2021000054A PE2021000054A PE20210185A1 PE 20210185 A1 PE20210185 A1 PE 20210185A1 PE 2021000054 A PE2021000054 A PE 2021000054A PE 2021000054 A PE2021000054 A PE 2021000054A PE 20210185 A1 PE20210185 A1 PE 20210185A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- acute
- amino acids
- solubilized
- sequence
- Prior art date
Links
- 108010007730 Apyrase Proteins 0.000 abstract 3
- 102000007347 Apyrase Human genes 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 abstract 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 2
- 238000012217 deletion Methods 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 102220468054 Brother of CDO_N73Q_mutation Human genes 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 230000009692 acute damage Effects 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102220004414 rs104894504 Human genes 0.000 abstract 1
- 102200148410 rs672601363 Human genes 0.000 abstract 1
- 102220068569 rs794727519 Human genes 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere a un polipeptido de apirasa humana solubilizada modificada, que comprende una secuencia seleccionada del grupo que consiste en SEQ ID NO:58, SEQ ID NO:72, SEQ ID NO:229, entre otros. Adicionalmente, la apirasa humana solubilizada presenta las siguientes modificaciones: i) la eliminacion N terminal de entre 30 y 50 aminoacidos de longitud; ii) la eliminacion C terminal de entre 20 y 40 aminoacidos; y c) la modificacion central que comprende una eliminacion de los aminoacidos 193 a 204 en relacion con la secuencia de CD39 de tipo salvaje de acuerdo con la SEQ ID NO:1, y/o una mutacion puntual que comprende una a cinco mutaciones puntuales en relacion con la secuencia CD39 de tipo salvaje, de acuerdo con la SEQ ID NO:1, que se selecciona del grupo que consiste en: K71E, N73Q, V95A, G102D, entre otros. Dicha apirasa humana modificada es util en el tratamiento del dano tisular, tal como una lesion cerebral aguda, insuficiencia aguda multiorganica, dano agudo debido a traumatismo y/o hipoxia, lesion renal aguda, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18184269 | 2018-07-18 | ||
| PCT/IB2019/056117 WO2020016804A1 (en) | 2018-07-18 | 2019-07-17 | Solubilized apyrases, methods and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210185A1 true PE20210185A1 (es) | 2021-02-02 |
Family
ID=62985993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000054A PE20210185A1 (es) | 2018-07-18 | 2019-07-17 | Apirasas solubilizadas, metodos y usos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20220356455A1 (es) |
| EP (1) | EP3824079A1 (es) |
| JP (2) | JP7425784B2 (es) |
| KR (1) | KR20210035806A (es) |
| CN (1) | CN112424346A (es) |
| AR (1) | AR115790A1 (es) |
| AU (1) | AU2019306821B2 (es) |
| BR (1) | BR112021000586A2 (es) |
| CA (1) | CA3103684A1 (es) |
| CL (1) | CL2021000129A1 (es) |
| CO (1) | CO2021000210A2 (es) |
| CR (1) | CR20210021A (es) |
| CU (1) | CU20210008A7 (es) |
| EA (1) | EA202190057A1 (es) |
| EC (1) | ECSP21002804A (es) |
| IL (1) | IL280191A (es) |
| JO (1) | JOP20210008A1 (es) |
| MA (1) | MA53177A (es) |
| MX (1) | MX2021000542A (es) |
| PE (1) | PE20210185A1 (es) |
| PH (1) | PH12021550122A1 (es) |
| SG (1) | SG11202011776RA (es) |
| TW (1) | TW202016299A (es) |
| UY (1) | UY38299A (es) |
| WO (1) | WO2020016804A1 (es) |
| ZA (1) | ZA202007187B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021243173A1 (en) * | 2020-05-28 | 2021-12-02 | Charm Sciences, Inc. | Methods and assemblies for sample analysis |
| WO2024023746A1 (en) | 2022-07-29 | 2024-02-01 | Novartis Ag | Improved production of cd39 variants |
| WO2024023745A1 (en) | 2022-07-29 | 2024-02-01 | Novartis Ag | Treatment for acute organ injury using cd39, recombinant cd39 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020002277A1 (en) * | 1998-10-16 | 2002-01-03 | Maliszewski Charles Richard | Inhibitors of platelet activation and recruitment |
| AU6425699A (en) | 1998-10-16 | 2000-05-08 | Cornell Research Foundation Inc. | Methods of inhibiting platelet activation and recruitment |
| US6867177B2 (en) | 1999-08-13 | 2005-03-15 | The Trustees Of Columbia University In The City Of New York | CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders |
| US7247300B1 (en) | 2002-11-07 | 2007-07-24 | Apt Therapeutics, Inc. | Therapeutic use of soluble CD39L3 |
| EP1861498A4 (en) | 2005-03-17 | 2009-06-24 | Ca Nat Research Council | EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME |
| WO2011088231A1 (en) * | 2010-01-13 | 2011-07-21 | Apt Therapeutics, Inc. | Apyrase therapy for bleeding conditions |
| EP3083677B1 (en) | 2013-12-20 | 2019-08-28 | Novartis AG | Novel eukaryotic cells and methods for recombinantly expressing a product of interest |
| US11203631B2 (en) | 2013-12-20 | 2021-12-21 | Novartis Ag | Eukaryotic cells and methods for recombinantly expressing a product of interest |
-
2019
- 2019-07-15 UY UY0001038299A patent/UY38299A/es unknown
- 2019-07-16 TW TW108125140A patent/TW202016299A/zh unknown
- 2019-07-16 AR ARP190102009A patent/AR115790A1/es unknown
- 2019-07-17 MA MA053177A patent/MA53177A/fr unknown
- 2019-07-17 SG SG11202011776RA patent/SG11202011776RA/en unknown
- 2019-07-17 KR KR1020217001187A patent/KR20210035806A/ko unknown
- 2019-07-17 PE PE2021000054A patent/PE20210185A1/es unknown
- 2019-07-17 EA EA202190057A patent/EA202190057A1/ru unknown
- 2019-07-17 JP JP2021502432A patent/JP7425784B2/ja active Active
- 2019-07-17 WO PCT/IB2019/056117 patent/WO2020016804A1/en active Application Filing
- 2019-07-17 CN CN201980047594.2A patent/CN112424346A/zh active Pending
- 2019-07-17 MX MX2021000542A patent/MX2021000542A/es unknown
- 2019-07-17 CU CU2021000008A patent/CU20210008A7/es unknown
- 2019-07-17 CR CR20210021A patent/CR20210021A/es unknown
- 2019-07-17 US US17/261,533 patent/US20220356455A1/en active Pending
- 2019-07-17 JO JOP/2021/0008A patent/JOP20210008A1/ar unknown
- 2019-07-17 CA CA3103684A patent/CA3103684A1/en active Pending
- 2019-07-17 AU AU2019306821A patent/AU2019306821B2/en active Active
- 2019-07-17 BR BR112021000586-2A patent/BR112021000586A2/pt unknown
- 2019-07-17 EP EP19769879.8A patent/EP3824079A1/en active Pending
-
2020
- 2020-11-18 ZA ZA2020/07187A patent/ZA202007187B/en unknown
-
2021
- 2021-01-14 EC ECSENADI20212804A patent/ECSP21002804A/es unknown
- 2021-01-14 IL IL280191A patent/IL280191A/en unknown
- 2021-01-14 CO CONC2021/0000210A patent/CO2021000210A2/es unknown
- 2021-01-15 CL CL2021000129A patent/CL2021000129A1/es unknown
- 2021-01-15 PH PH12021550122A patent/PH12021550122A1/en unknown
-
2023
- 2023-11-14 JP JP2023193640A patent/JP2024023297A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021000210A2 (es) | 2021-01-18 |
| MX2021000542A (es) | 2021-03-29 |
| WO2020016804A1 (en) | 2020-01-23 |
| CR20210021A (es) | 2021-03-23 |
| UY38299A (es) | 2020-02-28 |
| SG11202011776RA (en) | 2021-02-25 |
| IL280191A (en) | 2021-03-01 |
| MA53177A (fr) | 2021-05-26 |
| JP2024023297A (ja) | 2024-02-21 |
| KR20210035806A (ko) | 2021-04-01 |
| ZA202007187B (en) | 2022-06-29 |
| CL2021000129A1 (es) | 2021-08-20 |
| JP7425784B2 (ja) | 2024-01-31 |
| ECSP21002804A (es) | 2021-04-29 |
| CA3103684A1 (en) | 2020-01-23 |
| CU20210008A7 (es) | 2021-08-06 |
| EP3824079A1 (en) | 2021-05-26 |
| PH12021550122A1 (en) | 2021-09-27 |
| JOP20210008A1 (ar) | 2021-01-12 |
| AU2019306821B2 (en) | 2022-09-29 |
| JP2021529550A (ja) | 2021-11-04 |
| US20220356455A1 (en) | 2022-11-10 |
| AU2019306821A1 (en) | 2020-12-24 |
| EA202190057A1 (ru) | 2021-08-24 |
| CN112424346A (zh) | 2021-02-26 |
| TW202016299A (zh) | 2020-05-01 |
| AR115790A1 (es) | 2021-02-24 |
| BR112021000586A2 (pt) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210185A1 (es) | Apirasas solubilizadas, metodos y usos | |
| CO2018005306A2 (es) | Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia | |
| ECSP15042898A (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| NI202100085A (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| PE20150923A1 (es) | Moleculas de union il-17a novedosas y usos medicos de las mismas | |
| CO2017000614A2 (es) | Polipéptidos gdf15 modificados y composiciones de los mismos | |
| PE20191203A1 (es) | Variantes de alfa-glucosidasa acida y usos de las mismas | |
| AR070962A1 (es) | Uso de defensinas contra la tuberculosis | |
| MX2018016295A (es) | Interferon porcino pegilado y metodos de utilizacion del mismo. | |
| AR096162A1 (es) | Péptidos terapéuticos | |
| PE20180128A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| AR070276A1 (es) | Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion. | |
| EA200901459A1 (ru) | Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства | |
| PE20130199A1 (es) | Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores | |
| AR106624A1 (es) | Composiciones nutricionales que contienen butirato dietario y usos de las mismas | |
| PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
| BR112017014433A2 (pt) | proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica | |
| CO2022003556A2 (es) | Análogos de compstatina y sus usos médicos | |
| JP2020513810A5 (es) | ||
| UY37680A (es) | Proteína de fusión con polipéptido de extensión de vida media | |
| CO2020013221A2 (es) | Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos | |
| AR092736A1 (es) | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r | |
| BR112018000656A2 (pt) | peptídeos para uso na promoção do transporte de glicose |